Get started
Author

H. Lord

Observed names: H Lord, H.K. Lord, Hattie Lord
Institution: NHS Tayside
OpenAlex ID: A5108226708
Cetuximab is Effective, but more Toxic than Reported in the Bonner Trial
2007 · H.K. Lord, E. Junor, et al. · Clinical Oncology · 30
P34.01 6-Weekly vs 3-Weekly Pembrolizumab – Toxicities and Tolerance in The COVID-era
2021 · C. Douglas, H. Lord · Journal of Thoracic Oncology · 3
PDF
P17.12.b Investigating Short Term (<6 Months) Survivors of Glioblastoma - an Analysis of the Histo-mol Gbm Collaborative Database.
2025 · S D Robinson, S Lammy, et al. · Neuro-Oncology
PDF
Ks04.7.a Health-related Quality of Life and Cognitive Functioning in Survivors of Oligodendroglioma: an International Cross-sectional Investigation
2024 · F W Boele, S M Frances, et al. · Neuro-Oncology
PDF
A comparison of Gadolinium- and water-based blood-brain barrier dysfunction measures in patients with small vessel disease
2024 · Michael Stringer, Cameron Manning, et al. · Proceedings on CD-ROM - International Society for Magnetic Resonance in Medicine. Scientific Meeting and Exhibition/Proceedings of the International Society for Magnetic Resonance in Medicine, Scientific Meeting and Exhibition
37 Is it all in the head? The value of performing a CT brain in staging patients with non-small cell lung cancer (NSCLCa)
2016 · K.A. Morrison, H. Lord · Lung Cancer
40 Are we staging N2 disease in non-small cell lung cancer as accurately as possible? The NHS Tayside experience
2016 · J. Hart, H. Lord · Lung Cancer
65 Erlotinib: how good is it in a Scottish population?
2016 · M. Gallanagh, H. Lord · Lung Cancer
81 Audit of 1 year survival for patients receiving chemotherapy for NSCLC – all comers
2016 · J.L.E. Allison, H. Lord · Lung Cancer
85 What are the commonest toxicities for patients receiving chemotherapy for NSCLC? – a look at 6 months of data for all comers
2016 · J.L.E. Allison, H. Lord · Lung Cancer
80 Can we give SACT to patients with NSCLC on time and at full dose?
2016 · J.L.E. Allison, H. Lord · Lung Cancer
58 Is It Really Lung Cancer? An audit of patients without a histological diagnosis, but who are treated with non-surgical radical intent for lung cancer
2014 · F. Robertson, H.K. Lord · Lung Cancer
47 How are we doing? Clinical audit of patient survival and toxicities following adjuvant chemotherapy for non-small cell lung cancer in NHS Tayside 2005–2010
2013 · S. Costantino, H. Lord · Lung Cancer
27 Erlotinib – how does it fare in an unselected population? An NHS Tayside experience
2013 · J. Johnstone, E. Brown, et al. · Lung Cancer
20 An audit of docetaxel for 2nd line treatment of patients with advanced non small cell lung cancer (NSCLC): toxicities and outcomes in NHS Tayside 2005–2010
2012 · S. Capaldi, H. Lord, et al. · Lung Cancer
62 Audit of patients receiving cisplatin/pemetrexed chemotherapy for malignant mesothelioma in NHS Tayside 2005–2010
2012 · A. Cockburn, H. Lord, et al. · Lung Cancer
179 Why are patients with small cell lung cancer (SCLC) not given chemotherapy?
2012 · M.I. Khan, E.J. Brown, et al. · Lung Cancer
94 Audit on outcome of patients with brain metastases treated with palliative whole brain radiotherapy (WBRT) over a period of 12 months, a single institution's experience
2011 · C.L. Chaw, H.K. Lord · Lung Cancer
105 Survival outcomes following high dose palliative thoracic radiotherapy
2011 · J. Said, C.S. Barrie, et al. · Lung Cancer
102 Radical radiotherapy outcomes in stage I and II non-small cell lung cancer patients unfit for surgery
2011 · G. Ekatah, H.K. Lord · Lung Cancer
Are E6 and E7 Oncoproteins the Key Modulators of Radiosensitivity in HPV 16 and 18 Carcinoma Cell Lines?
2008 · H.K. Lord, D. Violot, et al. · International Journal of Radiation Oncology*Biology*Physics
PDF
Are E6 and E7 the key modulators of radiosensitivity in HPV 16 and 18 carcinoma cell lines?
2008 · H. Lord, A. Supiramaniam, et al. · Radioprotection
PDF
Frequency and significance of compound and double heterozygotes in a cohort of patients with Hypertrophic Cardiomyopathy
2008 · J Thistleton, Kate Thomson, et al. · Journal of Medical Genetics
Works count: 23
Citation count: 33
H-index: 2
I10-index: 1
Year
Topic
Type